Ex vivo exposure to calcitonin or raloxifene improves mechanical properties of diseased bone through non-cell mediated mechanisms.

[1]  Joseph M. Wallace,et al.  Combined Thermoneutral Housing and Raloxifene Treatment Improves Trabecular Bone Microarchitecture and Strength in Growing Female Mice , 2022, Calcified Tissue International.

[2]  S. Giannini,et al.  Bone Biopsy for Histomorphometry in Chronic Kidney Disease (CKD): State-of-the-Art and New Perspectives , 2021, Journal of clinical medicine.

[3]  A. Kaye,et al.  Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures. , 2021, Orthopedic reviews.

[4]  Jaimo Ahn,et al.  Immersion in Raloxifene does not significantly improve bone toughness or screw pull-out strength in multiple in vitro models , 2021, BMC Musculoskeletal Disorders.

[5]  M. Allen,et al.  Adenine-induced chronic kidney disease induces a similar skeletal phenotype in male and female C57BL/6 mice with more severe deficits in cortical bone properties of male mice , 2021, PloS one.

[6]  M. Allen,et al.  Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels. , 2021, Bone.

[7]  Joseph M. Wallace,et al.  Limited impacts of thermoneutral housing on bone morphology and mechanical properties in growing female mice exposed to external loading and raloxifene treatment. , 2021, Bone.

[8]  Joseph M. Wallace,et al.  Effects of Raloxifene and tibial loading on bone mass and mechanics in male and female mice , 2021, Connective tissue research.

[9]  Yajun Ma,et al.  Quantitative Ultrashort Echo Time (UTE) Magnetic Resonance Imaging of Bone: An Update , 2020, Frontiers in Endocrinology.

[10]  Joseph M. Wallace,et al.  6′-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding , 2020, Bone reports.

[11]  Joseph M. Wallace,et al.  Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone. , 2019, Bone.

[12]  E. Seeman.  Overview of bone microstructure, and treatment of bone fragility in chronic kidney disease , 2017, Nephrology.

[13]  M. Karsdal,et al.  A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. , 2016, Bone.

[14]  Joseph M. Wallace,et al.  Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta. , 2016, Matrix biology : journal of the International Society for Matrix Biology.

[15]  J. Almer,et al.  Effect of water on nanomechanics of bone is different between tension and compression. , 2016, Journal of the mechanical behavior of biomedical materials.

[16]  A. M. Kayastha,et al.  Ultra fast magic angle spinning solid – state NMR spectroscopy of intact bone , 2016, Magnetic resonance in chemistry : MRC.

[17]  M. J. Chalmers,et al.  Structural features underlying raloxifene's biophysical interaction with bone matrix. , 2016, Bioorganic & medicinal chemistry.

[18]  Aira Matsugaki,et al.  Altered material properties are responsible for bone fragility in rats with chronic kidney injury. , 2015, Bone.

[19]  Joseph M. Wallace,et al.  Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease , 2015, Kidney international.

[20]  G. Hutchins,et al.  In Vivo UTE‐MRI Reveals Positive Effects of Raloxifene on Skeletal‐Bound Water in Skeletally Mature Beagle Dogs , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  A. Felsenfeld,et al.  Calcitonin, the forgotten hormone: does it deserve to be forgotten? , 2015, Clinical kidney journal.

[22]  J. Nyman,et al.  The Role of Water Compartments in the Material Properties of Cortical Bone , 2015, Calcified Tissue International.

[23]  J. Nyman,et al.  Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease , 2015, Osteoporosis International.

[24]  C. Singh,et al.  Direct Evidence of Imino Acid-Aromatic Interactions in Native Collagen Protein by DNP-Enhanced Solid-State NMR Spectroscopy. , 2014, The journal of physical chemistry letters.

[25]  Joseph M. Wallace,et al.  Cortical Bone Mechanical Properties Are Altered in an Animal Model of Progressive Chronic Kidney Disease , 2014, PloS one.

[26]  Joseph M. Wallace,et al.  Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties. , 2014, Bone.

[27]  N. Chattopadhyay,et al.  Total Water, Phosphorus Relaxation and Inter-Atomic Organic to Inorganic Interface Are New Determinants of Trabecular Bone Integrity , 2013, PloS one.

[28]  Yan Wang,et al.  Water-mediated structuring of bone apatite. , 2013, Nature materials.

[29]  J. Nyman,et al.  Partial removal of pore and loosely bound water by low-energy drying decreases cortical bone toughness in young and old donors. , 2013, Journal of the mechanical behavior of biomedical materials.

[30]  P. Garnero.  The contribution of collagen crosslinks to bone strength. , 2012, BoneKEy reports.

[31]  R. Hamdy,et al.  Oral calcitonin , 2012, International journal of women's health.

[32]  A. LaCroix,et al.  Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women , 2012, Osteoporosis International.

[33]  M. Fukagawa,et al.  Effects of Raloxifene on Bone Mineral Metabolism in Postmenopausal Japanese Women on Hemodialysis , 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[34]  R. Rai,et al.  Dehydration-Induced Structural Changes in the Collagen–Hydroxyapatite Interface in Bone by High-Resolution Solid-State NMR Spectroscopy , 2011 .

[35]  M. Saito,et al.  Nonenzymatic Cross-Linking Pentosidine Increase in Bone Collagen and Are Associated with Disorders of Bone Mineralization in Dialysis Patients , 2011, Calcified Tissue International.

[36]  S. Cummings,et al.  Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. , 2011, Kidney international.

[37]  R. Guldberg,et al.  Effects of the Combination Treatment of Raloxifene and Alendronate on the Biomechanical Properties of Vertebral Bone , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  E. Shane,et al.  Bone mass and microarchitecture in CKD patients with fracture. , 2010, Journal of the American Society of Nephrology : JASN.

[39]  D. Burr.  Cortical bone: a target for fracture prevention? , 2010, The Lancet.

[40]  M. Morris,et al.  Time-resolved dehydration-induced structural changes in an intact bovine cortical bone revealed by solid-state NMR spectroscopy. , 2009, Journal of the American Chemical Society.

[41]  Joseph M. Wallace,et al.  Inbred Strain-Specific Response to Biglycan Deficiency in the Cortical Bone of C57BL6/129 and C3H/He Mice , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[42]  E. Shane,et al.  Chronic kidney disease and bone fracture: a growing concern. , 2008, Kidney international.

[43]  S. Cummings,et al.  The effect of raloxifene treatment in postmenopausal women with CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[44]  R. Qayyum,et al.  Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: A meta-analysis , 2008, Thrombosis and Haemostasis.

[45]  D. Burr,et al.  Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. , 2007, Endocrinology.

[46]  D. Burr,et al.  Raloxifene enhances vertebral mechanical properties independent of bone density. , 2006, Bone.

[47]  Michael D Morris,et al.  Three structural roles for water in bone observed by solid-state NMR. , 2006, Biophysical journal.

[48]  M. Ghoneim,et al.  A prospective randomized study for prevention of postrenal transplantation bone loss. , 2005, Kidney international.

[49]  S. Niemczyk,et al.  [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism]. , 2004, Polskie Archiwum Medycyny Wewnetrznej.

[50]  J. Ackerman,et al.  Detection of Hydroxyl Ions in Bone Mineral by Solid-State NMR Spectroscopy , 2003, Science.

[51]  M. Zaidi,et al.  Forty years of calcitonin--where are we now? A tribute to the work of Iain Macintyre, FRS. , 2002, Bone.

[52]  B. L. Riggs,et al.  Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  D. Black,et al.  Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[55]  P J Sinko,et al.  Oral delivery of salmon calcitonin. , 2000, Advanced drug delivery reviews.

[56]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[57]  C H Turner,et al.  Basic biomechanical measurements of bone: a tutorial. , 1993, Bone.

[58]  T. Karachalios,et al.  Calcitonin effects on rabbit bone. Bending tests on ulnar osteotomies. , 1992, Acta orthopaedica Scandinavica.

[59]  S. Giannini,et al.  Exogenous calcitonin protects against renal bone disease in rats with early renal failure. , 1987, Bone and mineral.

[60]  W. Nelp,et al.  Long-term calcitonin therapy in postmenopausal osteoporosis. , 1984, Metabolism: clinical and experimental.

[61]  J. Kanis,et al.  Responses to salmon calcitonin in chronic renal failure: relation to histological and biochemical indices of bone turnover , 1981, European journal of clinical investigation.

[62]  H. Kawashima,et al.  Calcitonin selectively stimulates 25-hydroxyvitamin D3-1α-hydroxylase in proximal straight tubule of rat kidney , 1981, Nature.

[63]  R. Robinson.  Physicochemical Structure of Bone , 1975 .

[64]  I. Macintyre,et al.  Thyroid origin of Calcitonin , 1964, Nature.

[65]  D. Copp,et al.  Calcitonin—a Hormone from the Parathyroid which Lowers the Calcium-level of the Blood , 1962, Nature.

[66]  J. J. Mecholsky,et al.  Fracture toughness and work of fracture of hydrated, dehydrated, and ashed bovine bone. , 2008, Journal of biomechanics.

[67]  J. Nyman,et al.  The influence of water removal on the strength and toughness of cortical bone. , 2006, Journal of biomechanics.